Alnylam

SILENCE DISEASE. AMPLIFY LIFE.™

Alnylam has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases in a different way - by silencing the genes that cause or contribute to them. We are working diligently to develop RNAi-based medicines to benefit as many patients as possible. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of RNAi therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.

Driven by Science, Inspired by People: Whether we're working to develop the first treatment for a disease, or a better one, patients are at the center of all we do. They are the reason we come to work every day, and their stories inspire us to continue innovating by pushing the science of RNAi therapeutics forward.

We are based in Cambridge, MA, USA, with offices throughout Europe, Asia, and South America.

Visit our social channels – LinkedIn and YouTube (@Alnylam Pharmaceuticals), X and Facebook (@Alnylam), and Instagram (@AlnylamPharma) – to learn more about the innovative work we are doing at Alnylam.

Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Fraudulent Recruitment Activity: Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."